Volume 21, Issue 4 , Pages 327-338, Winter 2009
Therapeutic Sentinel Lymph Node Imaging
Improving existing means of sentinel lymph node identification in non-small cell lung cancer will allow for molecular detection of occult micrometastases that may cause recurrence in early stage non-small cell lung cancer. Furthermore, targeted application of chemical and biological cytotoxic agents can potentially improve outcomes in patients with lymph node (LN) metastases. “Therapeutic Sentinel Lymph Node Imaging” incorporates these modalities into a single agent thereby identifying which LNs harbor tumor cells and simultaneously eradicating metastatic disease. In this review, we summarize the novel preclinical agents for identification and treatment of tumor bearing LNs and discuss their potential for clinical translation.
Keywords: sentinel lymph node, targeted, fluorescent imaging
To access this article, please choose from the options below
Supported in part by AACR-AstraZeneca Lung Cancer Translational Research Grant, AATS-Third Edward D. Churchill Research Scholarship, IASLC−International Association for the Study of Lung Cancer Young Investigator Award, and National Lung Cancer Partnership/LUNGevity Foundation Research Grants.
PII: S1043-0679(09)00138-5
doi:10.1053/j.semtcvs.2009.11.002
© 2009 Elsevier Inc. All rights reserved.
Volume 21, Issue 4 , Pages 327-338, Winter 2009
